Randomized Trial of ATN-224 and Temozolomide in Advanced Melanoma
Status:
Unknown status
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, phase II study to evaluate the safety and efficacy of oral
ATN-224 plus temozolomide in patients with advanced melanoma. Patients will be randomized
(1:1) between temozolomide and ATN-224 and temozolomide followed by ATN-224. Patients
assigned to the sequential treatment group will receive temozolomide until progression of
disease is documented and then receive ATN-224 as a single agent until documentation of
progression of disease using the last tumor assessment on temozolomide therapy as the
baseline assessment.